European Medicines Agency grants trehalose orphan drug designation for the treatment of amyotrophic lateral sclerosis

Trehalose, which crosses the blood brain barrier, stabilises proteins and activates autophagy through the activation of Transcription Factor EB. It has been shown in various disease models to reduce aggregation of misfolded proteins and accumulation of pathologic material.

Source:

Biospace Inc.